NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis $0.72 +0.05 (+7.54%) Closing price 04:00 PM EasternExtended Trading$0.72 +0.00 (+0.46%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Aldeyra Therapeutics Stock (NASDAQ:ALDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aldeyra Therapeutics alerts:Sign Up Key Stats Today's Range$0.61▼$0.7450-Day Range$0.56▼$1.4652-Week Range$0.53▼$5.93Volume850,563 shsAverage Volume1.69 million shsMarket Capitalization$43.56 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes.Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.Based in Lexington, Massachusetts, Aldeyra was founded in 2004 and is led by co-founder and Chief Executive Officer Todd C. Brady. Its medicines are investigational and are subject to clinical development and regulatory review.AI Generated. May Contain Errors. Read More Aldeyra Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreALDX MarketRank™: 3.839809134285 of 5 starsAldeyra Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 185th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingAldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialAldeyra Therapeutics has a consensus price target of $2.00, representing about 190.3% upside from its current price of $0.69.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.27) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.94% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 3.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aldeyra Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.76 News SentimentAldeyra Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aldeyra Therapeutics this week, compared to 6 articles on an average week.MarketBeat Follows1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Aldeyra Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $134,500.00 in company stock, which represents 0.3234% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $134,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.80% of the stock of Aldeyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDX Stock News HeadlinesAldeyra Therapeutics (NASDAQ:ALDX) Director Buys $128,000.00 in StockNovember 15, 2026 | insidertrades.comHC Wainwright Has Optimistic Opinion of ALDX FY2026 EarningsNovember 14, 2026 | americanbankingnews.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 19 at 1:00 AM | Digest Publishing (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Claritev (CTEV), Aldeyra Therapeutics (ALDX) and Argenx Se (ARGX)November 11, 2026 | theglobeandmail.comAldeyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6, 2026 | marketscreener.comMAldeyra Therapeutics, Inc. Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye DiseaseSeptember 29, 2026 | marketscreener.comMAldeyra Therapeutics plans formal FDA dispute resolution request for Reproxalap after third complete response letterSeptember 29, 2026 | msn.comAldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers RallySeptember 29, 2026 | benzinga.comSee More Headlines ALDX Stock Analysis - Frequently Asked Questions How have ALDX shares performed this year? Aldeyra Therapeutics' stock was trading at $5.18 at the beginning of 2026. Since then, ALDX stock has decreased by 86.7% and is now trading at $0.6890. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.05. When did Aldeyra Therapeutics IPO? Aldeyra Therapeutics (ALDX) raised $16 million in an initial public offering (IPO) on Friday, April 11th 2014. The company issued 1,500,000 shares at a price of $10.00-$12.00 per share. Who are Aldeyra Therapeutics' major shareholders? Top institutional investors of Aldeyra Therapeutics include Marshall Wace LLP (2.07%), Goldman Sachs Group Inc. (0.45%), State Street Corp (0.36%) and Algert Global LLC (0.15%). Insiders that own company stock include Perceptive Advisors Llc, Todd C Brady, Richard Douglas, Stephen Machatha, Bruce Greenberg and Michael Alfieri. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aldeyra Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Plug Power (PLUG). Company Calendar Last Earnings11/05/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ALDX's financial health is in the Red zone, according to TradeSmith. ALDX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ALDX CIK1341235 Webwww.aldeyra.com Phone781-761-4904Fax781-270-0630Employees6Year Founded2004Price Target and Rating Average Price Target for Aldeyra Therapeutics$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside+177.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.97% Return on Assets-33.34% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book1.24Miscellaneous Outstanding Shares60,357,000Free Float53,235,000Market Cap$43.56 million OptionableOptionable Beta1.32 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ALDX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredAlpha Oracle Signal drops to $7 for Black FridayThe Alpha Oracle Signal trading system is on sale for just $7 during a limited Black Friday deal. Others paid ...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.